Qing Xi Ooi supports clients with hands-on analysis and strategic advice

Viviana Moroso brings scientific depth to quality control

Siv Jönsson develops Pharmetheus’s learning agenda
Events
News

Contact us

Home
Publications

Publications

Below we provide links to posters, white papers and scientific publications by Pharmetheus affiliates in chronological order. Please note that access to some publications may require a subscription.

Search publications

Publications

27.06.23

Application of tumor size modelling and simulations to support the dose selection of BI 907828 for a Phase II study

Oncology

MIDD

Pharmacometrics

PAGE 31 (2023) Abstr 10465

Neldemo I, Sarr C, Friberg LE, Sailer R, Lamar M, Jayadeva G, Pérez-Pitarch A, Busse D

27.06.23

Mechanistic modelling of bioavailability and local immunogenicity after subcutaneous administration within the Open Systems Pharmacology framework

PBPK & PBBM

QSP

Immunology

PAGE 31 (2023) Abstr 10497

Pellowe M, Selvaggio G, Chenel M, Sjögren E

27.06.23

Population PK analysis of Pegaspargase in Japanese and non-Japanese patients with acute lymphoblastic leukemia

Oncology

Pharmacometrics

PAGE 31 (2023) Abstr 10549

Acharya C, Sarr C, Tessier A

27.06.23

Physiologically-based pharmacokinetic modelling of recombinant factor IX Fc fusion protein (rFIXFc) and recombinant FIX (rFIX) to characterize extravasation and binding to type IV collagen

PBPK & PBBM

Hematology

PAGE 31 (2023) Abstr 10615

Cloesmeijer ME, Sjögren E, Lenting PJ, Cnossen MH, Mathôt RAA

27.06.23

Application relevant shrinkage metrics

Pharmacometrics

PAGE 31 (2023) Abstr 10663

Bergstrand M

12.06.23

Bounded integer model-based analysis of psoriasis area and severity index in patients with moderate-to-severe plaque psoriasis receiving BI 730357

Immunology

Pharmacometrics

CPT Pharmacometrics Syst Pharmacol. 2023 Jun;12(6):758-769

Ooi QX, Kristoffersson A, Korell J, Flack M, Plan EL, Weber B

23.05.23

Development of a population pharmacokinetic model to characterize the pharmacokinetics of intrathecally administered tominersen in cerebrospinal fluid and plasma

MIDD

Trial design and analysis

Pharmacometrics

CNS

CPT Pharmacometrics Syst Pharmacol. 2023 Sep;12(9):1213-1226

Yamamoto Y, Sanwald Ducray P, Björnsson MA, Smart K, Grimsey P, Vatakuti S, Portron A, Massonnet B, Norris DA, Silber Baumann HE

01.04.23

Population Pharmacokinetics and Exposure-Response for Dapirolizumab Pegol From a Phase 2b Trial in Patients With Systemic Lupus Erythematosus

Immunology

Pharmacometrics

J Clin Pharmacol. 2023 Apr;63(4):435-444.

Acharya C, Magnusson MO, Vajjah P, Oliver R, Zamacona M

1 …171819… 34

Related content

16cefda6ef73b7faa4df913b326b6999f7619968 (1)

Science & Services

b794ade33e3aa54f89dcdaa2b69d3f48b3f73e5f (1)

Latest news

4033665f49ccf946b5c8406d016bbcdc6e406076 (1)

People & Culture

Contact

Pharmetheus AB
Kungsängstull 4  
753 19 Uppsala, Sweden

Visiting address:  
Dragarbrunnsgatan 77, 5th floor

LinkedIn
YouTube

Science & Services
Quick links

About Pharmetheus

Pharmetheus is a consultancy firm helping clients reduce uncertainty in technical and regulatory processes, increasing confidence in the development of new medicines that can improve patients’ lives.

Copyright © Pharmetheus AB 2026

Whistleblower
Privacy Policy
Cookie Policy